Drug Trial Radar · NCT07076407
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3)
Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
450
Planned (sponsor's estimate)
Start
Jul 8, 2025
Primary completion
May 2027
Study completion Jul 2027
Sponsor
- Lead sponsor
- Xenon Pharmaceuticals Inc.Industry
- Sponsor type
- Industry
- First posted
- Jul 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 74 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
X-NOVA3 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Conditions
- Major Depressive Disorder
Interventions
AzetukalnerDrug
Azetukalner 20 mg taken orally once a day with food (with the evening meal when possible) for 6 weeks
PlaceboDrug
Placebo taken orally once a day with food (with the evening meal when possible) for 6 weeks
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline in the Hamilton Depression Rating Scale, 17-item (HAMD-17) score at Week 6Time frame: Baseline to Week 6
Locations
50 sites in 7 countries. Site status is shown where the registry gives one.
Harmonex Neuroscience Research
Dothan, Alabama
University of Alabama at Birmingham, Huntsville Regional Medical Campus
Huntsville, Alabama
Pillar Clinical Research
Bentonville, Arkansas
SanRo Clinical Research Group
Bryant, Arkansas
Clinical Innovations Inc
Bellflower, California
Center for Neurohealth
La Jolla, California
Artemis Institute for Clinical Research
San Diego, California
California Neuroscience Research
Sherman Oaks, California
Pacific Clinical Research Management Group
Upland, California
Institute of Living
Hartford, Connecticut
Gulfcoast Clinical Research Center
Fort Myers, Florida
Sarkis Clinical Trials
Gainesville, Florida
Equipath Health and Research Tampa Bay, Llc
Riverview, Florida
Delricht Research
Atlanta, Georgia
Emory University Brain Health Center
Atlanta, Georgia
Advanced Quality Medical Research
Orland Park, Illinois
Smart Trials, LLC
Jefferson, Louisiana
Pharmasite Research Inc.
Baltimore, Maryland
Adams Clinical Boston
Boston, Massachusetts
Activmed Practices & Research, Llc - Methuen
Methuen, Massachusetts
Adams Clinical Watertown
Watertown, Massachusetts
Vitalix Clinical, Inc
Worcester, Massachusetts
Psychiatric Care and Research Center
O'Fallon, Missouri
St. Charles Psychiatric Associates - Midwest Research Group
Saint Charles, Missouri
Lumina Clinical Research Center
Cherry Hill, New Jersey
Princeton Medical Institute
Princeton, New Jersey
Bio Behavioral Health
Toms River, New Jersey
Bioscience Research, LLC
Mount Kisco, New York
Fieve Clinical Research, Inc.
New York, New York
IMA Clinical Research
New York, New York
Magnolia Clinical Research, Llc
Cary, North Carolina
Insight Clinical Trials
Independence, Ohio
Sooner Clinical Research
Oklahoma City, Oklahoma
Austin Clinical Trial Partners
Austin, Texas
Boeson Research
Provo, Utah
Suomen Terveystalo Oy
Helsinki, Finland
Oulu Mentalcare Oy
Oulu, Finland
Charite - Universitatsmedizin Berline
Berlin, Germany
Boehm-Peters PartGmbB - Praxis fur Psychiatrie, Psychotherapie, Neurologie
Rosenheim, Germany
In Vivo Sp. z.o.o.
Bydgoszcz, Poland
Showing 40 of 50 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.